Pfizer Inc.
30.03USD
-0.3900 (-1.28%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on PFE.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Price
Reading the stored fundamentals…
Dated 52-week rows are the highest and lowest CLOSE and the day each happened, which sits a little inside the intraday range a vendor quotes. Quotes are refreshed once a night — during a session the price above is the previous close.
Is the price low against peers, cash flow and analyst targets?
Do analysts expect earnings and revenue to keep growing?
1 of 6 checks could not be assessed (there is no analyst coverage stored).
Has the business grown and earned good returns on its filed numbers?
Can the balance sheet carry its debt?
1 of 6 checks could not be assessed (the stored data lacks the figures they need).
Is the dividend decent, covered and steady?
Only 2 of 6 checks could be assessed because there is not enough stored history and the stored data lacks the figures they need; 4 are needed.
An axis marked n/a has no vertex: it is left out of the shape rather than drawn as zero.
Each axis asks six plain questions of the stored data. A check that passes counts one. A check the stored data cannot answer is left out of the count, never counted as a fail, and an axis needs four answerable checks to show a result. Axes are never added together: there is no overall score. The thresholds are conventional rules of thumb and are blunt across sectors, so each check is listed with its rule and the figure it used.
P/E below peers
Trailing P/E is positive and below the median of its peers: the companies in its industry if there are at least 5, else its sector if at least 10, else the whole market if at least 30, always in the same currency.
P/E 39.0 against a peer median of 40.0 (9 USD companies in Drug Manufacturers - General).
Passed
PEG ratio
The PEG ratio is positive and at most 1.5.
PEG 13.76.
Did not pass
EV/EBITDA below peers
EV/EBITDA is positive and below the peer median, with peers chosen as for P/E. Not applied to financial companies.
EV/EBITDA 8.8 against a peer median of 14.5 (10 USD companies in Drug Manufacturers - General).
Passed
Price/book below peers
Price to book is positive and below the peer median, with peers chosen as for P/E.
Price/book 2.01 against a peer median of 7.79 (9 USD companies in Drug Manufacturers - General).
Passed
Statements: SEC filings, newest period 06/2026.
Peers: P/E against 9 USD companies in Drug Manufacturers - General; EV/EBITDA against 10 USD companies in Drug Manufacturers - General; price/book against 9 USD companies in Drug Manufacturers - General.
Rules of thumb applied to stored filings and quote data. Statements are as of the newest period shown above; multiples, analyst targets, estimates and yield come from a best-effort refresh and can lag by days. A count of plain checks, not a rating, a valuation or investment advice. Terms
Free cash flow yield
Free cash flow is at least 4.5% of market cap, the risk-free rate used across this site. Not applied to financial companies.
Free cash flow yield 6.4% against a 4.5% risk-free rate.
Passed
Analyst target above price
The mean analyst target is at least 15% above the last close, from at least 3 analysts. A published consensus, not a fair value.
Mean analyst target below the last close by 2.6% (26 analysts).
Did not pass
Earnings growth, next year
Consensus EPS for next fiscal year is at least 10% above this year's consensus, from at least 3 analysts.
Next year's EPS: consensus down 2.4% (22 analysts).
Did not pass
Earnings growth, this year
Consensus EPS for this fiscal year is at least 10% above last year's figure on the same street basis, from at least 3 analysts.
This year's EPS: consensus down 8.2% (24 analysts).
Did not pass
Revenue growth, next year
Consensus revenue for next fiscal year is at least 5% above this year's consensus, from at least 3 analysts.
Next year's revenue: consensus down 3.7% (23 analysts).
Did not pass
Revenue growth, this year
Consensus revenue for this fiscal year is at least 5% above last year's reported revenue, from at least 3 analysts.
This year's revenue: consensus down 0.6% (25 analysts).
Did not pass
Estimates rising
More analysts raised than cut this year's EPS estimate over the last 90 days, with at least 2 revisions in all.
No analyst estimates are stored for this security.
Not assessed
Revenue growth, latest quarter
Revenue in the latest quarter is at least 8% above the same quarter a year earlier.
Latest-quarter revenue up 2.6% on a year earlier.
Did not pass
Earnings growth, multi-year
Net income grew at least 5% a year over up to 5 fiscal years (at least 3 annual figures, positive at both ends).
Net income fell 3.2% a year, FY2020 to FY2025.
Did not pass
Earnings growth, last year
Net income over the latest twelve months is above the twelve months before it, and positive.
Net income down 59.7% (twelve months to 06/2026).
Did not pass
Revenue growth, multi-year
Revenue grew at least 3% a year over up to 5 fiscal years (at least 3 annual figures).
Revenue grew 8.5% a year, FY2020 to FY2025.
Passed
Return on equity
Return on equity is at least 15%: twelve-month net income over average equity. Not meaningful when equity is negative.
Return on equity 5.0%: twelve-month net income over the average equity.
Did not pass
Return on assets
Return on assets is at least 5%: twelve-month net income over average assets. Not applied to financial companies.
Return on assets 2.1%: twelve-month net income over the average assets.
Did not pass
Cash earnings
Operating cash flow over the latest twelve months is positive and at least net income. Not applied to financial companies.
Operating cash flow was at or above net income over the last twelve months.
Passed
Current ratio
Current assets are at least 1.0x current liabilities. Not applied to financial companies.
Current ratio 1.3x.
Passed
Short-term assets cover long-term liabilities
Current assets are at least the liabilities that fall due after a year (total liabilities less current liabilities). Not applied to financial companies.
Current assets are 0.5x the liabilities due after a year.
Did not pass
Debt to equity
Total debt is at most 100% of equity; no debt passes, negative equity with debt does not. Not applied to financial companies.
Total debt is 74% of equity.
Passed
Net debt to EBITDA
Net debt (total debt less cash) is at most 3.0x EBITDA; a net cash position passes. Not applied to financial companies.
Net debt is 2.5x EBITDA.
Passed
Interest cover
Operating income covers interest expense at least 3.0x; no debt passes. Not applied to financial companies.
The newest stored balance sheet lacks the figures this needs.
Not assessed
Cash flow to debt
Operating cash flow is at least 20% of total debt; no debt passes. Not applied to financial companies.
Operating cash flow is 21.2% of total debt.
Passed
Dividend yield
The dividend yield is at least 2%.
Dividend yield 5.73%.
Passed
Payout ratio
Dividends paid are at most 75% of net income. Not applied to real estate companies, whose net income is after depreciation.
Payout ratio 226% (Yahoo's figure).
Did not pass
Free cash flow cover
Free cash flow covers the dividends paid at least 1.0x. Not applied to financial companies.
Dividends paid are not in the stored cash-flow statements.
Not assessed
Paid every year
A dividend was paid in every one of the last 4 to 8 fiscal years stored (consecutive years, all present). A year missing from the filings data is not read as no dividend, so a gap makes this not assessed.
Dividends paid is missing for FY2018: absent from the filings data is not the same as not paid, so it is not judged.
Not assessed
No cuts
Total dividends paid never fell by more than 20% from one fiscal year to the next in that window.
Dividends paid is missing for FY2018: absent from the filings data is not the same as not paid, so it is not judged.
Not assessed
Growing dividend
Total dividends paid grew at least 3% a year across that window. The total, not per share: no per-share dividend history is stored.
Dividends paid is missing for FY2018: absent from the filings data is not the same as not paid, so it is not judged.
Not assessed